| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 05/06/2024 | 13:00 | GlobeNewswire Inc. | 23andMe Launches New Genetic Report on Bipolar Disorder | NASDAQ:ME | 23andMe Holding Company |
| 04/06/2024 | 13:00 | GlobeNewswire Inc. | 23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community | NASDAQ:ME | 23andMe Holding Company |
| 03/06/2024 | 14:06 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ME | 23andMe Holding Company |
| 03/06/2024 | 14:00 | GlobeNewswire Inc. | 23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting | NASDAQ:ME | 23andMe Holding Company |
| 29/05/2024 | 14:00 | GlobeNewswire Inc. | Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history | NASDAQ:ME | 23andMe Holding Company |
| 23/05/2024 | 23:15 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ME | 23andMe Holding Company |
| 23/05/2024 | 22:05 | GlobeNewswire Inc. | 23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results | NASDAQ:ME | 23andMe Holding Company |
| 14/05/2024 | 13:00 | GlobeNewswire Inc. | Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals | NASDAQ:ME | 23andMe Holding Company |
| 09/05/2024 | 22:50 | GlobeNewswire Inc. | 23andMe to Report Q4 and Full Year FY2024 Financial Results | NASDAQ:ME | 23andMe Holding Company |
| 30/04/2024 | 17:00 | Business Wire | Potter Handy Law Firm Represents Nearly 5,000 Clients in 23andMe Data Breach Case | NASDAQ:ME | 23andMe Holding Company |
| 24/04/2024 | 22:05 | GlobeNewswire Inc. | 23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | NASDAQ:ME | 23andMe Holding Company |
| 18/04/2024 | 14:00 | GlobeNewswire Inc. | 23andMe announces CEO’s intention to pursue a potential take-private | NASDAQ:ME | 23andMe Holding Company |
| 05/04/2024 | 22:05 | GlobeNewswire Inc. | 23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024 | NASDAQ:ME | 23andMe Holding Company |
| 20/03/2024 | 12:30 | GlobeNewswire Inc. | 23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6 | NASDAQ:ME | 23andMe Holding Company |
| 19/03/2024 | 13:00 | GlobeNewswire Inc. | 23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago | NASDAQ:ME | 23andMe Holding Company |
| 06/03/2024 | 13:30 | GlobeNewswire Inc. | 23andMe Launches New Genetic Reports on Common Forms of Cancer | NASDAQ:ME | 23andMe Holding Company |
| 05/03/2024 | 22:30 | GlobeNewswire Inc. | 23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024 | NASDAQ:ME | 23andMe Holding Company |
| 07/02/2024 | 22:07 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ME | 23andMe Holding Company |
| 07/02/2024 | 22:01 | GlobeNewswire Inc. | 23andMe Reports Third Quarter Fiscal 2024 Financial Results | NASDAQ:ME | 23andMe Holding Company |
| 06/02/2024 | 13:00 | Business Wire | Moneta Gold and Nighthawk Gold Complete At-Market Merger to form STLLR Gold Inc. | NASDAQ:ME | 23andMe Holding Company |
| 31/01/2024 | 04:12 | GlobeNewswire Inc. | 23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay | NASDAQ:ME | 23andMe Holding Company |
| 30/01/2024 | 23:00 | Business Wire | Nighthawk Gold Obtains Final Court Order for the Proposed Arrangement | NASDAQ:ME | 23andMe Holding Company |
| 24/01/2024 | 22:05 | GlobeNewswire Inc. | 23andMe to Report FY2024 Third Quarter Financial Results | NASDAQ:ME | 23andMe Holding Company |
| 22/01/2024 | 14:00 | Business Wire | Moneta Gold and Nighthawk Gold Announce the Proposed Directors for the MergeCo Board | NASDAQ:ME | 23andMe Holding Company |
| 19/12/2023 | 14:00 | GlobeNewswire Inc. | 23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts | NASDAQ:ME | 23andMe Holding Company |
| 01/12/2023 | 22:06 | Edgar (US Regulatory) | Form 8-K/A - Current report: [Amend] | NASDAQ:ME | 23andMe Holding Company |
| 28/11/2023 | 13:15 | Business Wire | Nighthawk and Moneta Announce At-Market Merger to Create a Leading Canadian Gold Development Company | NASDAQ:ME | 23andMe Holding Company |
| 08/11/2023 | 22:05 | GlobeNewswire Inc. | 23andMe Reports Second Quarter Fiscal 2024 Financial Results | NASDAQ:ME | 23andMe Holding Company |
| 07/11/2023 | 14:00 | GlobeNewswire Inc. | 23andMe Launches Total Health™, its Comprehensive, Prevention-Based Health Membership | NASDAQ:ME | 23andMe Holding Company |
| 06/11/2023 | 14:00 | GlobeNewswire Inc. | 23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 | NASDAQ:ME | 23andMe Holding Company |